ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 11.2 USD 0.18% Market Closed
Market Cap: 1.1B USD
Have any thoughts about
ARS Pharmaceuticals Inc?
Write Note

ARS Pharmaceuticals Inc
Net Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ARS Pharmaceuticals Inc
Net Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income CAGR 3Y CAGR 5Y CAGR 10Y
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Net Income
-$54.4m
CAGR 3-Years
-18%
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Net Income
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
5%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%
No Stocks Found

ARS Pharmaceuticals Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

In the competitive landscape of biotechnology, ARS Pharmaceuticals Inc. positions itself as a transformative player with a focused mission to innovate life-saving medical treatments. The company concentrates on the development of novel therapeutics aimed at treating severe and life-threatening allergic reactions. Its flagship product, a nasal spray designed to deliver epinephrine quickly and effectively, stands as a testament to its innovative efforts. By channeling resources into this potentially groundbreaking delivery mechanism, ARS Pharmaceuticals seeks to address the critical need for patient-friendly solutions in emergency situations, where traditional methods like auto-injectors may be less ideal. Through relentless research and strategic development, the company aims to make these treatments more accessible and user-friendly, potentially expanding their reach within the healthcare market. ARS Pharmaceuticals generates revenue through the commercialization of its therapies, primarily targeting the lucrative segments associated with allergy treatments. Key to their financial strategy is securing regulatory approvals, which opens pathways for product launches and subsequent revenue channels. Furthermore, leveraging strategic partnerships and collaborations within the pharmaceutical industry enhances their market presence. Such alliances allow ARS Pharmaceuticals to tap into established distribution networks, maximizing both reach and revenue potential. Their business model underscores a commitment not only to innovation but also to scalability, aiming to establish a sustainable revenue stream as the demand for efficient allergy treatments grows. This strategic positioning reflects a thorough understanding of market needs and a keen ability to adapt to the ever-evolving healthcare landscape.

SPRY Intrinsic Value
12.05 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is ARS Pharmaceuticals Inc's Net Income?
Net Income
-54.4m USD

Based on the financial report for Dec 31, 2023, ARS Pharmaceuticals Inc's Net Income amounts to -54.4m USD.

What is ARS Pharmaceuticals Inc's Net Income growth rate?
Net Income CAGR 5Y
-25%

Over the last year, the Net Income growth was -57%. The average annual Net Income growth rates for ARS Pharmaceuticals Inc have been -18% over the past three years , -25% over the past five years .

Back to Top